Abstract
In the case of cancer immunity, specific T cells against tumor associated antigens have been shown to be effective. In a bone marrow transplantation setting, adoptive transfer of Epstein Bar virus-specific T cells or infusion of donor lymphocytes, following relapse of chronic myelogenous leukemia, have proven their therapeutic potential. Theoretically, adoptive transfer therapy with highly purified and large quantities of specific CD8+ cytotoxic T lymphocytes (CTL) is desirable for many cancer patients, either in the allogeneic or autologous setting. Disadvantages of this approach include: 1) The high degree of difficulty to clone and expand the required numbers of specific CTL; 2) The patient-specific nature of this approach (MHC restriction); 3) The emergence of new escape variants that have lost the specific target antigens for these CTL; 4) The sophisticated and labor intensive infrastructure required, making this therapy extremely costly.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480–83.
Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-rumor vaccine efficacy. Nat Med 1999;5:774–79.
Medzhitov R, Janeway C. Innate immune recognition: mechanisms and pathways. Immunol Rev 2000;173:89–97.
Schuurhuis DFL Laban S, Toes RE, et al. Immature dendritic cells acquire CD8+ cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 1998;192:145–50.
Winzler C, Rovere P, Rescigno M, et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997; 185:317–28.
Van Bergen J, Ossendorp F, Jordens R, Mommaas AM, Drijfhout JW, Koning F. Get into the groove! Targeting antigens to MHC class II. Immunol Rev 1999;172:87–96.
Tanaka K, Kasahara M. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-D-inducible proteasome activator PA28. Immunol Rev 1998;163:161–76.
Ossendorp F, Camps M, Granucci F, et al. Maturation of dendritic cells improves CTL epitope processing through up-regulation of proteasome acti-vator-subunit PA28y. 2003; Submitted for publication.
Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 2002;168:2240–46.
Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA. 1996;93:7855–60.
Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350–58.
Van Mierlo GJ, den Boer AT, Medema JP, et al. CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA. 2002;99:5561–66.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media Dordrecht
About this paper
Cite this paper
Ossendorp, F., van der Burg, S., Toes, R., Offringa, R., Melief, C. (2003). Cellular Immunotherapy — Towards Direct DC Activation for Licence to Kill. In: Sibinga, C.T.S., De Leij, L.F.M.H. (eds) Cellular Engineering and Cellular Therapies. Developments in Hematology and Immunology, vol 38. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3718-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3718-9_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5250-9
Online ISBN: 978-1-4757-3718-9
eBook Packages: Springer Book Archive